ATE486592T1 - Memantin für die behandlung von leichtem bis mittelschwerem morbus alzheimer - Google Patents

Memantin für die behandlung von leichtem bis mittelschwerem morbus alzheimer

Info

Publication number
ATE486592T1
ATE486592T1 AT05711256T AT05711256T ATE486592T1 AT E486592 T1 ATE486592 T1 AT E486592T1 AT 05711256 T AT05711256 T AT 05711256T AT 05711256 T AT05711256 T AT 05711256T AT E486592 T1 ATE486592 T1 AT E486592T1
Authority
AT
Austria
Prior art keywords
mild
disease
memantine
treatment
moderate alzheimer
Prior art date
Application number
AT05711256T
Other languages
English (en)
Inventor
Scott Mcdonald
Ivan Gergel
Albrecht Stoeffler
Hans-Joerg Moebius
Yvonne Wirth
Steven Potkin
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34798833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE486592(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Application granted granted Critical
Publication of ATE486592T1 publication Critical patent/ATE486592T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
AT05711256T 2004-01-05 2005-01-05 Memantin für die behandlung von leichtem bis mittelschwerem morbus alzheimer ATE486592T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53455304P 2004-01-05 2004-01-05
US54217604P 2004-02-04 2004-02-04
PCT/US2005/000145 WO2005067908A2 (en) 2004-01-05 2005-01-05 Memantine for the treatment of mild and mild-to-moderate alzheimer’s disease

Publications (1)

Publication Number Publication Date
ATE486592T1 true ATE486592T1 (de) 2010-11-15

Family

ID=34798833

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05711256T ATE486592T1 (de) 2004-01-05 2005-01-05 Memantin für die behandlung von leichtem bis mittelschwerem morbus alzheimer

Country Status (17)

Country Link
US (2) US20060020042A1 (de)
EP (1) EP1703902B1 (de)
AT (1) ATE486592T1 (de)
AU (1) AU2005204358B2 (de)
CA (1) CA2551689A1 (de)
CY (1) CY1111359T1 (de)
DE (1) DE602005024511D1 (de)
DK (1) DK1703902T3 (de)
HR (1) HRP20110035T1 (de)
IL (1) IL176689A0 (de)
NZ (1) NZ548327A (de)
PL (1) PL1703902T3 (de)
PT (1) PT1703902E (de)
RS (1) RS51540B (de)
RU (1) RU2371173C2 (de)
SI (1) SI1703902T1 (de)
WO (1) WO2005067908A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006121560A2 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
CA2655799A1 (en) * 2005-06-22 2006-12-28 Develogen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
EP2004656B1 (de) * 2006-04-07 2013-07-10 Boehringer Ingelheim International GmbH Thienopyrimidine mit mnk1/mnk2-hemmender wirkung für pharmazeutische zusammensetzungen
EP1889847A1 (de) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidine zur pharmazeutischen Anwendung
KR20090041447A (ko) * 2006-08-21 2009-04-28 노파르티스 아게 알츠하이머 질환 진행에 대한 바이오마커
US20080182908A1 (en) * 2007-01-25 2008-07-31 Vinita Umashankar Vyas Pharmaceutical compositions comprising memantine
WO2009065596A2 (en) * 2007-11-22 2009-05-28 Develogen Aktiengesellschaft Use of mnk inhibitors for the treatment of alzheimer's disease
CA2735361A1 (en) 2008-08-26 2010-03-04 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
US8580833B2 (en) 2009-09-30 2013-11-12 Transtech Pharma, Inc. Substituted imidazole derivatives and methods of use thereof
AR080328A1 (es) * 2010-02-26 2012-03-28 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros
MX2012009735A (es) * 2010-02-26 2012-09-12 Boehringer Ingelheim Int 4-[cicloalquiloxi (hetero) arilamino] tieno [2,3-d] pirimidinas que tienen actividad inhibitoria de mnk1/mnk2 para composiciones farmaceuticas.
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
WO2013043597A1 (en) * 2011-09-19 2013-03-28 The Feinstein Institute For Medical Research Identification and uses of brain activity networks
JP5404750B2 (ja) * 2011-11-22 2014-02-05 シャープ株式会社 認知症ケア支援方法、認知症情報出力装置、認知症ケア支援システム、及びコンピュータプログラム
FR2983732B1 (fr) * 2011-12-09 2013-11-22 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent
WO2014015047A1 (en) 2012-07-17 2014-01-23 The General Hospital Corporation Compositions and methods to treat neurodegenerative diseases
US9717710B2 (en) 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
EP3019865A4 (de) * 2013-07-12 2017-04-05 Immuneering Corporation Systeme, verfahren und umgebung zur automatisierten überprüfung von genomdaten zur identifikation einer herunterregulierten und/oder unregulierten genexpression als zeichen einer erkrankung oder eines leidens
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
EP3864008A1 (de) 2018-10-10 2021-08-18 vTv Therapeutics LLC Metaboliten von [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amin
MX2021008751A (es) * 2019-01-25 2021-11-12 Univ Brown Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad.
US20210002650A1 (en) * 2019-07-03 2021-01-07 University Of Virginia Patent Foundation Compositions and methods for treating alzheimer's disease
KR102271305B1 (ko) * 2020-05-21 2021-06-30 주식회사 아리바이오 치매 예방 및 치료용 조성물
EP4190319A4 (de) 2020-07-29 2024-05-01 Novamedica Limited Liability Company Pharmazeutische zusammensetzung mit memantin und citicolin
KR102272907B1 (ko) * 2020-11-05 2021-07-05 주식회사 아리바이오 치매 예방 및 치료용 조성물
WO2023248206A1 (en) * 2022-06-24 2023-12-28 Aribio Co., Ltd. Compositions and methods for preventing and treating neurodegenerative diseases
WO2024003784A1 (en) * 2022-06-29 2024-01-04 Aribio Co., Ltd. Composition for preventing and treating neurodegenerative diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA974518A (en) * 1972-04-20 1975-09-16 Merz And Co. Procedure for the manufacture of 1,3,5 trisubstituted adamantan compounds
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
DE10299048I2 (de) * 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5958919A (en) * 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
TW593225B (en) * 1997-06-30 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane NMDA receptor antagonists
US20040102525A1 (en) * 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
DE60324788D1 (de) * 2002-05-31 2009-01-02 Lundbeck & Co As H Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit
GEP20094759B (en) * 2002-10-24 2009-08-25 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
EP1603548A4 (de) * 2003-02-05 2007-10-10 Myriad Genetics Inc Verfahren und zusammensetzung zur behandlung neurodegenerativer erkrankungen

Also Published As

Publication number Publication date
US20100048726A1 (en) 2010-02-25
US20060020042A1 (en) 2006-01-26
EP1703902A2 (de) 2006-09-27
WO2005067908A3 (en) 2005-11-10
DE602005024511D1 (de) 2010-12-16
PT1703902E (pt) 2010-11-17
RS51540B (en) 2011-06-30
DK1703902T3 (da) 2011-02-14
HRP20110035T1 (hr) 2011-02-28
PL1703902T3 (pl) 2011-04-29
RU2007129842A (ru) 2009-02-10
IL176689A0 (en) 2006-10-31
CY1111359T1 (el) 2015-08-05
CA2551689A1 (en) 2005-07-28
WO2005067908A2 (en) 2005-07-28
SI1703902T1 (sl) 2011-02-28
RU2371173C2 (ru) 2009-10-27
NZ548327A (en) 2009-06-26
AU2005204358A1 (en) 2005-07-28
EP1703902B1 (de) 2010-11-03
AU2005204358B2 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
ATE486592T1 (de) Memantin für die behandlung von leichtem bis mittelschwerem morbus alzheimer
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ECSP055719A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
MX2007001679A (es) Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
WO2005076819A3 (en) Chlorite in the treatment of neurodegenerative disease
ATE383853T1 (de) Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit
EA200700708A1 (ru) Мемантин для лечения расстройств поведения детского возраста
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
EA200501479A1 (ru) Ifn-бета в отдельности или в комбинации с другими лекарственными средствами для лечения болезни альцгеймера и нарушений, связанных с деменцией
JP2018502884A5 (de)
ATE371724T1 (de) Behandlung neurodegenerativer krankheiten
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
ATE392471T1 (de) Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren
GT200400231A (es) Compuestos de sulfoniltetrahidro-3h-benzo(e)indol-8-amina como ligandos de la 5-hidroxitriptamina-6.
EA200501865A1 (ru) Аналоги тиовольфраматов и их применение
DE602004026597D1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
ATE494903T1 (de) Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden
ATE495750T1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
ATE453386T1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
SG153698A1 (en) Composition and method for prevention and treatment of alzheimeræs disease
BR0308753A (pt) Método para produzir pseudo-ilhotas
TR201900152T4 (tr) Sinükleinopatik ve amiloidojenik hastalıkların önlenmesi ve tedavisi.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1703902

Country of ref document: EP